Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Public ClinicalTrials.gov record NCT06109779. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.
Study identification
- NCT ID
- NCT06109779
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 760 participants
Conditions and interventions
Conditions
Interventions
- Rilvegostomig Drug
- Placebo Drug
- Capecitabine Drug
- Gemcitabine/Cisplatin Drug
- S-1 [Tegafur/Oteracil/gimeracil] Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 4, 2023 (Actual)
- Primary completion
- Jan 2, 2029 (Estimated)
- Completion
- May 3, 2030 (Estimated)
- Last update posted
- Oct 16, 2026
2023 – 2030
United States locations
- U.S. sites
- 22
- U.S. states
- 18
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35233 | — |
| Research Site | Phoenix | Arizona | 85054 | — |
| Research Site | Los Angeles | California | 90089 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Stanford | California | 94305 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Littleton | Colorado | 80129 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Jacksonville | Florida | 32224 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Iowa City | Iowa | 52242 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Lexington | Kentucky | 40506 | — |
| Research Site | New Orleans | Louisiana | 70121 | — |
| Research Site | Grand Rapids | Michigan | 49503 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Commack | New York | 11725 | — |
| Research Site | Mineola | New York | 11501 | — |
| Research Site | Philadelphia | Pennsylvania | 19144 | — |
| Research Site | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 154 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06109779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06109779 live on ClinicalTrials.gov.